CRISPR Interference to Inhibit Oncogenes for Cancer Therapy
International Journal of Molecular Sciences · 16.04.2026 · 27 (8) · 3564
DOI: 10.3390/ijms27083564 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 16.04.2026. Verfasst von Bin Guo. Beteiligte Einrichtung: Department of Pharmacological and Pharmaceutical Sciences, University of Houston, Houston, TX 77204, USA. Hauptthemen laut MEDLINE: Neoplasms, Oncogenes, CRISPR-Cas Systems, Genetic Therapy. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 101 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIH HHS, National Institute of Health.
Abstract (Originalsprache)
CRISPR interference (CRISPRi), a programmable transcriptional repression technology derived from nuclease-deficient CRISPR-Cas systems, has emerged as a powerful method for selectively inhibiting oncogene expression without altering the genomic DNA. This feature offers a major advantage over other oncogene targeting technologies such as CRISPR-mediated gene knockout, mRNA inhibition by siRNA or miRNA, or small-molecule inhibitors of the proteins encoded by the oncogenes, especially in cancers driven by transcriptional dysregulation or otherwise undruggable oncogenes. Here, I present a comprehensive review of CRISPRi mechanisms, delivery strategies, and preclinical applications in oncology (including advances in targeting core oncogenic drivers like MYC and KRAS). The advantages of CRISPRi as well as in vivo validation of CRISPRi-mediated tumor suppression are discussed. Finally, I outline translational challenges and future directions for incorporating CRISPRi into precision cancer therapies. The accumulated evidence suggests that CRISPRi could become a cornerstone for next-generation gene-regulatory therapeutics.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Pharmacological and Pharmaceutical Sciences, University of Houston, Houston, TX 77204, USA.
ORCID-Profile: Bin Guo
Förderung
- NIH HHS
- National Institute of Health
Zitieren
APA
Guo, B. (2026). CRISPR Interference to Inhibit Oncogenes for Cancer Therapy. International Journal of Molecular Sciences, 27(8), 3564. https://doi.org/10.3390/ijms27083564
Vancouver
Guo B. CRISPR Interference to Inhibit Oncogenes for Cancer Therapy. International Journal of Molecular Sciences. 2026;27(8):3564. doi:10.3390/ijms27083564
BibTeX
@article{Guo2026,
author = {Guo, Bin},
title = {CRISPR Interference to Inhibit Oncogenes for Cancer Therapy},
journal = {International Journal of Molecular Sciences},
year = {2026},
volume = {27},
number = {8},
pages = {3564},
doi = {10.3390/ijms27083564}
}
EUVIMED